Morgan Stanley Alzamend Neuro, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.49 - $0.77 $1,207 - $1,898	-2,465 Reduced 83.14%	500 $0
Q1 2023 May 15, 2023	SELL	$0.37 - $0.71 $1,369 - $2,627	-3,700 Reduced 55.51%	2,965 $1,000
Q4 2022 Feb 14, 2023	BUY	$0.53 - $222.0 $1,571 - $658,230	2,965 Added 80.14%	6,665 $3,000
Q3 2022 Nov 14, 2022	SELL	$0.88 - $178.5 $176 - $35,700	-200 Reduced 5.13%	3,700 $4,000
Q2 2022 Oct 27, 2022	BUY	$0.82 - $1.2 $82 - $120	100 Added 2.63%	3,900 $3,000
Q2 2022 Aug 15, 2022	BUY	$0.82 - $1.2 $82 - $120	100 Added 2.63%	3,900 $3,000
Q1 2022 Oct 27, 2022	SELL	$0.91 - $2.23 $91 - $223	-100 Reduced 2.56%	3,800 $5,000
Q1 2022 May 13, 2022	BUY	$0.91 - $2.23 $3,458 - $8,474	3,800 New	3,800 $5,000
Q4 2021 Feb 14, 2022	SELL	$1.9 - $3.08 $619 - $1,004	-326 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.28 - $7.68 $743 - $2,503	326 New	326 $1,000

Ticker ALZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,481,800
Market Cap $122M
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.